81 related articles for article (PubMed ID: 12848894)
1. Epidermal Growth Factor Receptor: A Novel Target for Anticancer Treatment.
Pandey M; Chandramohan K
World J Surg Oncol; 2003 Jul; 1(1):9. PubMed ID: 12848894
[No Abstract] [Full Text] [Related]
2. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
4. Novel combinations based on epidermal growth factor receptor inhibition.
Adjei AA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
[TBL] [Abstract][Full Text] [Related]
5. Off-target effects of epidermal growth factor receptor antagonists mediate retinal ganglion cell disinhibited axon growth.
Douglas MR; Morrison KC; Jacques SJ; Leadbeater WE; Gonzalez AM; Berry M; Logan A; Ahmed Z
Brain; 2009 Nov; 132(Pt 11):3102-21. PubMed ID: 19783665
[TBL] [Abstract][Full Text] [Related]
6. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer.
Scartozzi M; Pierantoni C; Berardi R; Antognoli S; Bearzi I; Cascinu S
Anal Quant Cytol Histol; 2006 Apr; 28(2):61-8. PubMed ID: 16637508
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor as a therapeutic target in lung cancer.
Schiller JH
Semin Respir Crit Care Med; 2004; 25 Suppl 1():11-6. PubMed ID: 16088516
[TBL] [Abstract][Full Text] [Related]
9. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
[TBL] [Abstract][Full Text] [Related]
12. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies.
van Cruijsen H; Giaccone G; Hoekman K
Int J Cancer; 2005 Dec; 117(6):883-8. PubMed ID: 16152621
[TBL] [Abstract][Full Text] [Related]
14. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
15. Advances in target therapy for lung cancer.
Mitsudomi T
Jpn J Clin Oncol; 2010 Feb; 40(2):101-6. PubMed ID: 20031962
[TBL] [Abstract][Full Text] [Related]
16. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
Qiu Q; Domarkas J; Banerjee R; Katsoulas A; McNamee JP; Jean-Claude BJ
Anticancer Drugs; 2007 Feb; 18(2):171-7. PubMed ID: 17159603
[TBL] [Abstract][Full Text] [Related]
17. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor family.
Bazley LA; Gullick WJ
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S17-27. PubMed ID: 16113093
[TBL] [Abstract][Full Text] [Related]
19. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
20. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
Budman DR; Soong R; Calabro A; Tai J; Diasio R
Anticancer Drugs; 2006 Sep; 17(8):921-8. PubMed ID: 16940802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]